Repurposing Dantrolene for Long-term Combination Therapy to Potentiate Antisense-Mediated DMD Exon-Skipping in the mdx mouse
Page 1 of 1
Repurposing Dantrolene for Long-term Combination Therapy to Potentiate Antisense-Mediated DMD Exon-Skipping in the mdx mouse
Jon Moulton Thu Feb 22, 2018 9:59 am
Wang DW, Mokhonova EI, Genevieve C. Kendall GC, Becerra D, Naeini YB, Cantor RM, Spencer MJ, Nelson SF, Miceli MC. Repurposing Dantrolene for Long-term Combination Therapy to Potentiate Antisense-Mediated DMD Exon-Skipping in the mdx mouse. Molec Ther Nucl Acids. 2018;[Epub ahead of print] doi:10.1016/j.omtn.2018.02.002
Jon Moulton- Posts : 5721
Join date : 2010-03-12
Age : 62
Location : Philomath, Oregon, USA -
Similar topics» Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy
» Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies
» Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
» Combination antisense treatment for destructive exon skipping of myostatin and open reading frame rescue of dystrophin in neonatal mdx mice
» Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice
» Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy For Tauopathies
» Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
» Combination antisense treatment for destructive exon skipping of myostatin and open reading frame rescue of dystrophin in neonatal mdx mice
» Combination Antisense Treatment for Destructive Exon Skipping of Myostatin and Open Reading Frame Rescue of Dystrophin in Neonatal mdx Mice
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum